Contributions
Abstract: EP1353
Type: ePoster
Abstract Category: Clinical aspects of MS - Paediatric MS
Background: Multiple sclerosis (MS) in early childhood is exceptionally rare, and there is little information about relapse preventing therapies in this population.
Objective: To investigate clinical characteristics and tolerance of weekly intramuscular interferon beta-1a (IFNβ-1a) of MS in children below 4 years old.
Methods: A retrospective chart review at a single institution was conducted for consecutive patients who were diagnosed with MS and who took IFNβ-1a below 4 years old.
Results: The subject consisted of 2 boys and 2 girls ranging in age from 1.7 to 3.1 years at the moment of the first demyelinating symptoms. Various initial symptoms were presented including ataxia, facial paresis, status epilepticus, and encephalopathy. The mean age of diagnosis with definite MS according to the revised McDonald"s criteria (2010) was 3.0 years (range: 2.5-3.3). All patients were diagnosed with relapsing-remitting multiple sclerosis. Mean age of initiating IFNβ-1a was 3.3 years (range: 3.1-3.5) with a mean time since initial disease onset of 1.0 year (range: 0.4-1.5). Initial doses ranged from 3 to 6 µg for the subjects as 1/10-1/5 doses of adult. After several months from the initiation, doses were increased and maintained from 9 to 15 µg. In the mean duration of IFNβ-1a of 2.2 years (range: 0.6-4.3), 4 patients showed flu-like symptoms and one patient showed elevation of liver enzyme. Although one patient discontinued IFNβ-1a because of frequent relapses, no patient discontinued therapy due to severe adverse events. Mean annualized relapse rate of pre and on IFNβ-1a was 1.43 and 0.35, respectively. Final expanded disability status scale was 0.0 in 3 patients and 1.0 in one patient.
Conclusions: This case series showed clinical course of very early-onset MS, and suggests that the reduced dose of IFNβ-1a is tolerated in MS below 4 years old.
Disclosure:
Masahiro Nishiyama has received grant-in-aid for scientific research from the Japan Society for the Promotion of Science (KAKENHI 15K19614).
Satoshi Takada has received support from Bando Chemical Industries, Ltd.
Kazumoto Iijima has received support from Daiichi Sankyo Co. Ltd
The remaining authors have nothing to disclose.
Abstract: EP1353
Type: ePoster
Abstract Category: Clinical aspects of MS - Paediatric MS
Background: Multiple sclerosis (MS) in early childhood is exceptionally rare, and there is little information about relapse preventing therapies in this population.
Objective: To investigate clinical characteristics and tolerance of weekly intramuscular interferon beta-1a (IFNβ-1a) of MS in children below 4 years old.
Methods: A retrospective chart review at a single institution was conducted for consecutive patients who were diagnosed with MS and who took IFNβ-1a below 4 years old.
Results: The subject consisted of 2 boys and 2 girls ranging in age from 1.7 to 3.1 years at the moment of the first demyelinating symptoms. Various initial symptoms were presented including ataxia, facial paresis, status epilepticus, and encephalopathy. The mean age of diagnosis with definite MS according to the revised McDonald"s criteria (2010) was 3.0 years (range: 2.5-3.3). All patients were diagnosed with relapsing-remitting multiple sclerosis. Mean age of initiating IFNβ-1a was 3.3 years (range: 3.1-3.5) with a mean time since initial disease onset of 1.0 year (range: 0.4-1.5). Initial doses ranged from 3 to 6 µg for the subjects as 1/10-1/5 doses of adult. After several months from the initiation, doses were increased and maintained from 9 to 15 µg. In the mean duration of IFNβ-1a of 2.2 years (range: 0.6-4.3), 4 patients showed flu-like symptoms and one patient showed elevation of liver enzyme. Although one patient discontinued IFNβ-1a because of frequent relapses, no patient discontinued therapy due to severe adverse events. Mean annualized relapse rate of pre and on IFNβ-1a was 1.43 and 0.35, respectively. Final expanded disability status scale was 0.0 in 3 patients and 1.0 in one patient.
Conclusions: This case series showed clinical course of very early-onset MS, and suggests that the reduced dose of IFNβ-1a is tolerated in MS below 4 years old.
Disclosure:
Masahiro Nishiyama has received grant-in-aid for scientific research from the Japan Society for the Promotion of Science (KAKENHI 15K19614).
Satoshi Takada has received support from Bando Chemical Industries, Ltd.
Kazumoto Iijima has received support from Daiichi Sankyo Co. Ltd
The remaining authors have nothing to disclose.